Abstracts tagged "clinical trial"

Abstract Number: 1010 • ACR Convergence 2022
Comparison of Established and New, Preliminarily Proposed ASAS Cut-Offs for Inflammatory MRI Lesions in the Sacroiliac Joints of Axial Spondyloarthritis Patients and Implications for Recruitment in Clinical Studies
Xenofon Baraliakos¹, Pedro Machado², Lars Bauer³, Bengt Hoepken³, Mindy Kim⁴, Thomas Kumke³, Rachel Tham⁵ and Martin Rudwaleit⁶, ¹Rheumazentrum Ruhrgebiet Herne, Herne, Germany, ²University College London, London, United Kingdom, ³UCB Pharma, Monheim am Rhein, Germany, ⁴UCB Pharma, Smyrna, GA, ⁵UCB Pharma, Slough, UK, Overland Park, KS, ⁶University of Bielefeld, Klinikum Bielefeld, Bielefeld; Germany Klinikum Bielefeld and Charité Berlin, Germany, and Gent University, Gent, Belgium
Background/Purpose: The Assessment of SpondyloArthritis international Society (ASAS) recently proposed preliminary, more stringent, data-driven definitions for active and structural MRI lesions of the sacroiliac joint…
Abstract Number: 1528 • ACR Convergence 2022
Nintedanib in Patients with Systemic Sclerosis-Associated Interstitial Lung Disease (SSc-ILD) and Organ Damage: Data from the SENSCIS Trial
Janet Pope¹, Susanna Proudman², Wendy Stevens³, Joerg Henes⁴, Rozeta Simonovska⁵, Margarida Alves⁶ and Yannick Allanore⁷, ¹University of Western Ontario, London, ON, Canada, ²Rheumatology Unit, Royal Adelaide Hospital, and Discipline of Medicine, University of Adelaide, Adelaide, Australia, ³Department of Rheumatology, St Vincent’s Hospital, Melbourne, Australia, Melbourne, Australia, ⁴Center for Interdisciplinary Clinical Immunology, Rheumatology and Auto-inflammatory Diseases (INDIRA), University Hospital Tübingen, Tübingen, Germany, ⁵mainanalytics GmbH, Sulzbach (Taunus), Germany, Sulzbach (Taunus), Germany, ⁶Boehringer Ingelheim International GmbH, Ingelheim am Rhein, Germany, ⁷Department of Rheumatology A, Descartes University, APHP, Cochin Hospital, Paris, France, Paris, France
Background/Purpose: The Scleroderma Clinical Trials Consortium Damage Index (SCTC-DI) was developed to quantify organ damage in patients with SSc. We assessed outcomes in the SENSCIS…
Abstract Number: 1807 • ACR Convergence 2022
Reduction in Monosodium Urate Crystal Deposit Volume During the MIRROR RCT Trial in Patients Treated with Pegloticase Plus Methotrexate Co-therapy: A Serial Dual-Energy Computed Tomography (DECT) Analysis
Nicola Dalbeth¹, John Botson², kenneth saag³, Ada Kumar⁴, Lissa Padnick-Silver⁵, Brian LaMoreaux⁵ and Fabio Becce⁶, ¹University of Auckland, Auckland, New Zealand, ²Orthopedic Physicians Alaska, Anchorage, AK, ³University of Alabama at Birmingham, Birmingham, AL, ⁴Horizon Therapeutics, Deerfield, IL, ⁵Horizon Therapeutics plc, Deerfield, IL, ⁶Lausanne University Hospital (CHUV), Lausanne, Switzerland
Background/Purpose: Dual-energy computed tomography (DECT) can reliably visualize and quantify monosodium urate (MSU) crystal deposits in gout patients.1 Two MIRROR open-label trial (pegloticase + oral…
Abstract Number: 1985 • ACR Convergence 2022
The BEGIN Study: A Double-blind, Multi-center, Two-part, Randomized, Placebo-controlled Study of the Safety, Tolerability, and Efficacy of 4 Weeks of Treatment with AP1189 in Early Rheumatoid Arthritis (RA) Patients with Active Joint Disease
Thomas Jonassen¹, Irene Sandholdt², Birgitte Telmer² and Ellen-Margrethe Hauge³, ¹SynAct Pharma, Holte, Denmark, ²CroxxMed, Hørsholm, Denmark, ³Department of Rheumatology, Aarhus University Hospital, Aarhus, Denmark
Background/Purpose: Melanocortin (MC) type 1 and type 3 receptor stimulation is associated with anti-inflammatory activity and the promotion of inflammatory resolution. AP1189 is novel biased…
Abstract Number: 2115 • ACR Convergence 2022
Early Skin and Early Enthesitis Responses in Psoriatic Arthritis Patients Treated with Guselkumab Associate with Long-term Response: Post Hoc Analysis Through 2 Years of a Phase 3 Study
Laura Coates¹, Julio Ramírez², Dennis McGonagle³, Sibel Aydin⁴, Miriam Zimmermann⁵, Francois Nantel⁶, May Shawi⁷, Emmanouil Rampakakis⁸, Peter Nash⁹ and Philip J Mease¹⁰, ¹Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences, University of Oxford, Oxford, UK, Oxford, England, United Kingdom, ²Arthritis Unit, Rheumatology Department, Hospital Clinic, Barcelona, Spain, ³University of Leeds, Leeds, UK, Leeds, United Kingdom, ⁴University of Ottawa, Ottawa Hospital Research Institute, Ottawa, ON, Canada, ⁵Immunology, Janssen Scientific Affairs, LLC, Zug, Switzerland, ⁶Nantel MedSci Consult, Montréal, QC, Canada, ⁷Immunology Global Medical Affairs, Janssen Pharmaceutical Companies of Johnson & Johnson, Horsham, PA, ⁸McGill University, Department of Pediatrics and JSS Medical Research, Montréal, QC, Canada, ⁹School of Medicine, Griffith University, Sunshine Coast, Australia, ¹⁰Swedish Medical Center/Providence St. Joseph Health, Seattle, WA
Background/Purpose: Guselkumab (GUS), an IL-23p19 inhibitor, has demonstrated efficacy in PsA across key Group for Research and Assessment of Psoriasis (PsO) and Psoriatic Arthritis (GRAPPA)-recommended…
Abstract Number: 0295 • ACR Convergence 2022
Safety and Efficacy of Upadacitinib in Patients with Rheumatoid Arthritis and Inadequate Response to Conventional Synthetic DMARDs: Results Through 5 Years from the SELECT-NEXT Study
Gerd Burmester¹, Filip Van den bosch², John Tesser³, Anna K Shmagel⁴, Yuanyuan Duan⁴, Nasser Khan⁵, Heidi Camp⁶ and Alan Kivitz⁷, ¹Charité University Medicine Berlin, Berlin, Germany, ²Department of Internal Medicine and Paediatrics, Ghent University and VIB Centre for Inflammation Research, Ghent, Belgium, ³Arizona Arthritis & Rheumatology Associates, Phoenix, AZ, ⁴AbbVie, Inc., North Chicago, IL, ⁵AbbVie, Inc., Abbott Park, IL, ⁶Abbvie, Winnetka, IL, ⁷Department of Rheumatology, Altoona Center for Clinical Research, Duncansville, PA
Background/Purpose: In the phase 3 SELECT-NEXT study, upadacitinib (UPA) demonstrated efficacy at wk 12 and sustained efficacy up to wk 60 in patients with rheumatoid…
Abstract Number: 0371 • ACR Convergence 2022
A Phase 2, Double-blind, Randomized, Placebo-Controlled Multicenter Study to Evaluate Efficacy, Safety, and Tolerability of JBT-101/Lenabasum in Systemic Lupus Erythematosus, an Autoimmunity Centers of Excellence Study (ALE09)
Meggan Mackay¹, Robert Zurier², Diane Kamen³, Fotios Koumpouras⁴, Anca Askanase⁵, Kenneth Kalunian⁶, Steffan Schulz⁷, Giovanni Franchin⁸, Nancy Olsen⁹, Andreea Coca¹⁰, Roberto Caricchio¹¹, Maureen McMahon¹², Maria Dall'Era¹³, Amit Saxena¹⁴, Megan Clowse¹⁵, Stanley Ballou¹⁶, Linna Ding¹⁷, Beverly Welch¹⁸, Jessica Springer¹⁹, Andrew Shaw¹, Lynette Keyes-Elstein²⁰, Kaitlyn Steinmiller²¹, Amanda Mickey²¹, Cynthia Aranow¹ and Betty Diamond¹, ¹Feinstein Institutes for Medical Research, Manhasset, NY, ²Feinstein Institutes, Wyckoff, NJ, ³Medical University of South Carolina, Charleston, SC, ⁴Yale School of Medicine, New Haven, CT, ⁵Columbia University Medical Center, New York, NY, ⁶University of California San Diego, La Jolla, CA, ⁷Univ Pennsylvania, Philadelphia, PA, ⁸BronxCare, Feinstein Institutes, Manhasset, NY, ⁹Penn State University/Milton S Hershey, Hershey, PA, ¹⁰UPMC, Pittsburgh, PA, ¹¹Lewis Katz School of Medicine at Temple University, Philadelphia, PA, ¹²University of California Los Angeles, Los Angeles, CA, ¹³University of California, Division of Rheumatology, San Francisco, CA, ¹⁴NYU School of Medicine, New York, NY, ¹⁵Duke University, Durham, NC, ¹⁶Case Western Reserve University - Metro Health, Cleveland, OH, ¹⁷NIH NIAID, Rhockvile, MD, ¹⁸NIAID/NIH, Bethesda, MD, ¹⁹NIH/NIAID, Rockville, MD, ²⁰Rho, Chapel Hill, NC, ²¹Rho Inc, Durham, NC
Background/Purpose: Musculoskeletal (MSK) symptoms are common in SLE, often associate with debilitating pain requiring immunosuppressive treatment. JBT-101 is a non-psychotropic, non-immunosuppressive, cannabinoid receptor 2 agonist…
Abstract Number: 0546 • ACR Convergence 2022
COmparison of the Effect of Treatment with NSAIDs Added to Anti-TNF Therapy versus Anti-TNF Therapy Alone on Progression of StrUctural Damage in the Spine over Two Years in Patients with Ankylosing Spondylitis (CONSUL): An Open-Label, Randomized Controlled, Multicenter Trial
Fabian Proft¹, Bukrhard Muche², valeria Rios-Rodriguez³, Murat Torgutalp⁴, Mikhail Protopopov⁵, Joachim Listing⁶, Maryna Verba⁷, Jan Brandt-Juergens⁸, Uta Kiltz⁹, Maren Sieburg¹⁰, Swen Jacki¹¹, Joachim Sieper⁴ and Denis Poddubnyy¹, ¹Department of Gastroenterology, Infectious Diseases and Rheumatology, Charité – Universitätsmedizin Berlin, Berlin, Germany, ²Charité University Hospital, CCM, Berlin, Germany, ³Charité-Universitätsmedizin Berlin, Berlin, Germany, ⁴Charité - Universitätsmedizin, Berlin, Berlin, Germany, ⁵Charité Universitätsmedizin Berlin, Berlin, Germany, ⁶German Rheumatism Research Centre, Epidemiology Unit, Berlin, Germany, ⁷Charité – Universitätsmedizin Berlin, Department of Gastroenterology, Infectiology and Rheumatology (including Nutrition Medicine), Berlin, Germany, ⁸Rheumatologische Schwerpunktpraxis, Berlin, Germany, ⁹Rheumazentrum Ruhrgebiet, Herne, Germany, ¹⁰Rheumatologische Facharztpraxis, Magdeburg, Germany, ¹¹Rheumatologische Schwerpunktpraxis, Tübingen, Germany
Background/Purpose: There is some evidence that NSAIDs, in particular celecoxib (CEL), might possess not only symptomatic efficacy but also disease-modifying properties in ankylosing spondylitis (AS),…
Abstract Number: 1015 • ACR Convergence 2022
Predictors of Nail Response with Guselkumab: A Post Hoc Analysis of the VOYAGE 2 Clinical Trial
Alexander Egeberg¹, William Tillett², Enikö Sonkoly³, Patricia Gorecki⁴, Anna Tjärnlund⁵, Jozefien Buyze⁶, Sven Wegner⁷ and Dennis McGonagle⁸, ¹Department of Dermatology, Bispebjerg Hospital, Copenhagen, Denmark, ²Royal National Hospital for Rheumatic Diseases, Bath, United Kingdom, ³Dermatology and Venereology Division, Karolinska Institutet; Center for Molecular Medicine, Karolinska Institutet, Stockholm, Sweden, ⁴Janssen-Cilag Ltd, High Wycombe, United Kingdom, ⁵Janssen-Cilag AB, Solna, Sweden, ⁶Janssen Pharmaceutica NV, Beerse, Belgium, ⁷Janssen-Cilag GmbH, Neuss, Germany, ⁸Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds; National Institute for Health Research, Leeds Biomedical Research Centre, Leeds Teaching Hospitals NHS Trust, Leeds, United Kingdom
Background/Purpose: Understanding factors that impact response to therapy may help improve disease management, clinical outcomes and patient quality of life. Nails are often overlooked in…
Abstract Number: 1531 • ACR Convergence 2022
Continued Treatment with Nintedanib in Patients with Systemic Sclerosis-Associated Interstitial Lung Disease (SSc-ILD): Three-Year Data from SENSCIS-ON
Yannick Allanore¹, Madelon Vonk², Oliver Distler³, Arata Azuma⁴, Maureen Mayes⁵, Alexandra James⁶, Veronika Kohlbrenner⁷, Margarida Alves⁸, Dinesh Khanna⁹ and Kristin Highland¹⁰, ¹Department of Rheumatology A, Descartes University, APHP, Cochin Hospital, Paris, France, Paris, France, ²Department of Rheumatology, Radboud University Medical Center, Nijmegen, Netherlands, ³Department of Rheumatology, University Hospital Zurich, University of Zurich, Zürich, Switzerland, ⁴Department of Pulmonary Medicine and Oncology, Graduate School of Medicine, Nippon Medical School, Tokyo, Japan, ⁵Division of Rheumatology and Clinical Immunogenetics, University of Texas McGovern Medical School, Houston, TX, ⁶Elderbrook solutions GmbH, Bietigheim-Bissingen, Germany, Bietigheim-Bissingen, Germany, ⁷Boehringer Ingelheim Pharmaceuticals, Inc., Ridgefield, Connecticut, USA, Ridgefield, CT, ⁸Boehringer Ingelheim International GmbH, Ingelheim am Rhein, Germany, ⁹Division of Rheumatology, Department of Internal Medicine, Scleroderma Program, University of Michigan, Ann Arbor, MI, ¹⁰Cleveland Clinic, Cleveland, Ohio, USA, Cleveland, OH
Background/Purpose: In the randomized placebo-controlled SENSCIS trial in patients with SSc-ILD, nintedanib reduced the rate of decline in forced vital capacity (FVC) (mL/year) over 52…
Abstract Number: 1808 • ACR Convergence 2022
Assessing the Role of the NLRP3 Inflammasome in Driving Inflammation in Affected Joints of Patients with Inter-critical Gout
Swamy Venuturupalli¹, Ami Ben-artzi², Tasmia Amjad³, Amit Kumar⁴, Nikhil Davuluri³, Timothy Chu³, Umair Khan³, Diego Parra³, Natalie Fortune³ and Caroline Jefferies¹, ¹Cedars-Sinai Medical Center, Los Angeles, CA, ²Ami Ben-Artzi, MD Inc., Beverly Hills, CA, ³Attune Health, Beverly Hills, CA, ⁴Attune Health, Beverly Hils, CA
Background/Purpose: Percutaneous ultrasound-guided needle synovial biopsies can now be performed at the bedside. To date, no synovial biopsy studies have been conducted in gout patients.…
Abstract Number: 1996 • ACR Convergence 2022
Individual Patient Data Meta-analysis on Continued Use of Glucocorticoids After Their Use as Bridging Therapy in Patients with Rheumatoid Arthritis
Lotte van Ouwerkerk¹, Patrick Verschueren², Pascal de Jong³, Paul Emery⁴, Josef Smolen⁵, Robert Landewé⁶, Willem Lems⁷, Maarten Boers⁸, Tom Huizinga¹, CF Allaart¹ and Sytske Anne Bergstra⁹, ¹Leiden University Medical Center, Leiden, Netherlands, ²University Hospital Leuven, Leuven, Belgium, ³ErasmusMC, Hendrik Ido Ambacht, Netherlands, ⁴Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, Leeds, United Kingdom, ⁵Medical University of Vienna, Vienna, Austria, ⁶Amsterdam University Medical Center, Meerssen, Netherlands, ⁷Amsterdam University Medical Centers, Amsterdam, Netherlands, ⁸Amsterdam UMC, Vrije Universiteit, Amsterdam, Netherlands, ⁹LUMC, Leiden, Netherlands
Background/Purpose: Short-term (< 3 months) treatment with glucocorticoids (GC) ("bridging") is recommended in the EULAR 2019 rheumatoid arthritis (RA) recommendations when starting a csDMARD in…
Abstract Number: 2117 • ACR Convergence 2022
Bimekizumab Improvements in Efficacy on Disease Activity Assessed via Composite Endpoints in Biologic DMARD-naïve and TNFi-IR Patients with Active PsA: Pooled 16-Week Results from Phase 3 Randomized, Placebo-Controlled Studies
Philip J Mease¹, Laura Coates², Robert Landewé³, Iain B McInnes⁴, Christopher Ritchlin⁵, Tatsuya Atsumi⁶, Frank Behrens⁷, Dafna Gladman⁸, Laure Gossec⁹, Peter Nash¹⁰, Barbara Ink¹¹, Deepak Assudani¹¹, Rajan Bajracharya¹¹, Jason Coarse¹², Adam R Prickett¹³ and Alice Gottlieb¹⁴, ¹Swedish Medical Center/Providence St. Joseph Health, Seattle, WA, ²Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences, University of Oxford, Oxford, UK, Oxford, England, United Kingdom, ³Amsterdam University Medical Center, Meerssen, Netherlands, ⁴Institute of Infection, Immunity and Inflammation, College of Medical, Veterinary and Life Sciences, University of Glasgow, Glasgow, Scotland, United Kingdom, ⁵Allergy, Immunology and Rheumatology Division, University of Rochester Medical School, Canandaigua, NY, ⁶Hokkaido University, Sapporo, Japan, ⁷Rheumatology University Hospital & Fraunhofer Institute Translational Medicine and Pharmacology, Goethe-University Frankfurt, Frankfurt Am Main, Germany, ⁸Toronto Western Hospital, Schroeder Arthritis Institute, Toronto, ON, Canada, ⁹Sorbonne Université, Paris, France, ¹⁰School of Medicine, Griffith University, Sunshine Coast, Australia, ¹¹UCB Pharma, Slough, United Kingdom, ¹²UCB Pharma, Raleigh, NC, USA, Raleigh, NC, ¹³UCB Pharma, Brussels, Belgium, ¹⁴Department of Dermatology, The Icahn School of Medicine at Mount Sinai, New York, NY
Background/Purpose: Psoriatic arthritis (PsA) is a disease with multiple manifestations; it is important that the efficacy of new interventions is assessed by composite endpoints across…
Abstract Number: 0001 • ACR Convergence 2022
12-month Findings of the Randomized, Double-Blind, Placebo-Controlled, Multicenter, Efficacy and Safety Study of Methotrexate to Increase Response Rates in Patients with Uncontrolled GOut Receiving Pegloticase (MIRROR RCT)
John Botson¹, kenneth saag², Jeff Peterson³, Katie Obermeyer⁴, Brian LaMoreaux⁴, Suneet Grewal⁵, Amar Majjhoo⁶, John Tesser⁷ and Michael Weinblatt⁸, ¹Orthopedic Physicians Alaska, Anchorage, AK, ²University of Alabama at Birmingham, Birmingham, AL, ³Western Washington Arthritis Clinic, Seattle, WA, ⁴Horizon Therapeutics plc, Deerfield, IL, ⁵East Bay Rheumatology Medical Group, Inc., San Leandro, CA, ⁶Shores Rheumatology, PC, Troy, MI, ⁷Arizona Arthritis & Rheumatology Associates, Phoenix, AZ, ⁸Brigham and Women's Hospital, Harvard Medical School, Boston, MA
Background/Purpose: The MIRROR RCT trial examined pegloticase (PEGylated uricase) safety and efficacy with methotrexate (MTX) vs placebo (PBO) as co-therapy. Sustained urate-lowering rate during Month…
Abstract Number: 0297 • ACR Convergence 2022
Effect of Upadacitinib, Adalimumab, and Placebo on Residual Pain Among Patients with Rheumatoid Arthritis Whose Inflammation Was Attenuated After Three and Six Months of Treatment
Louis Bessette¹, Adriana Kakehasi², Neil Basu³, David A. Walsh⁴, Andra Balanescu⁵, Clifton Bingham⁶, Andrew Garrison⁷, Ivan Lagunes⁸, sander strengholt⁹, Ralph Lippe¹⁰ and Maxime Dougados¹¹, ¹Centre de l'Ostoporose et de Rhumatologie de Québec, Québec, QC, Canada, ²Federal University of Minas Gerais, Hospital das Clínicas, Belo Horizonte, Brazil, ³University of Glasgow, Glasgow, Scotland, United Kingdom, ⁴University of Nottingham, Nottingham, United Kingdom, ⁵University of Medicine and Pharmacy Carol Davila, Bucharest, Romania, ⁶Johns Hopkins University, Baltimore, MD, ⁷AbbVie, Inc., North Chicago, IL, ⁸AbbVie, Inc., Mettawa, IL, ⁹AbbVie, Inc., Abcoude, Netherlands, ¹⁰AbbVie, Inc, Wiesbaden, Germany, ¹¹Université de Paris, Paris, France
Background/Purpose: Residual pain remains a challenge that prevents patients (pts) with RA from achieving a better quality of life. Current RA treatments have demonstrated efficacy…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].